Contract manufacturers, laboratories, and packagers are responsible for selecting and monitoring qualified firms and, in some cases, their suppliers. These entities and their suppliers are subject to inspections by the U.S. Food and Drug Administration (FDA) at any time. Violations, including failure to comply with current Good Manufacturing Practices (cGMP), can result in enforcement actions that may disrupt operations or drug distribution. After product approval, the FDA may impose restrictions, require recalls, mandate post-marketing studies, implement risk minimization plans, or conduct surveillance. Non-compliance can lead to adverse publicity, enforcement actions, warning letters, corrective advertising, and penalties. Changes to drug labeling or additional risk management measures may be required based on new safety or effectiveness data.
Pharmaceutical drug distribution is regulated with requirements for record-keeping, licensing, storage, and security to prevent unauthorized sales. Under the Food and Drug Omnibus Reform Act (FDORA), sponsors must notify the FDA of changes in marketing status within 180 days to avoid product discontinuation. Additional government regulations and evolving FDA policies may delay or prevent drug approvals.
Manufacturing, sales, promotion, and post-approval activities are regulated by multiple U.S. authorities beyond the FDA, including the Centers for Medicare & Medicaid Services, divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety and Health Administration, the Environmental Protection Agency, and state and local governments. Sales, marketing, and educational programs must comply with fraud and abuse laws, and pricing and rebate programs must adhere to Medicaid rebate requirements and other applicable legislation.
Blueprint Medicines's Comment on Supply Chain
Contract manufacturers, laboratories, and packagers are responsible for selecting and monitoring qualified firms and, in some cases, their suppliers. These entities and their suppliers are subject to inspections by the U.S. Food and Drug Administration (FDA) at any time. Violations, including failure to comply with current Good Manufacturing Practices (cGMP), can result in enforcement actions that may disrupt operations or drug distribution. After product approval, the FDA may impose restrictions, require recalls, mandate post-marketing studies, implement risk minimization plans, or conduct surveillance. Non-compliance can lead to adverse publicity, enforcement actions, warning letters, corrective advertising, and penalties. Changes to drug labeling or additional risk management measures may be required based on new safety or effectiveness data.
Pharmaceutical drug distribution is regulated with requirements for record-keeping, licensing, storage, and security to prevent unauthorized sales. Under the Food and Drug Omnibus Reform Act (FDORA), sponsors must notify the FDA of changes in marketing status within 180 days to avoid product discontinuation. Additional government regulations and evolving FDA policies may delay or prevent drug approvals.
Manufacturing, sales, promotion, and post-approval activities are regulated by multiple U.S. authorities beyond the FDA, including the Centers for Medicare & Medicaid Services, divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety and Health Administration, the Environmental Protection Agency, and state and local governments. Sales, marketing, and educational programs must comply with fraud and abuse laws, and pricing and rebate programs must adhere to Medicaid rebate requirements and other applicable legislation.
Sources:
Blueprint Medicines Corporation's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Blueprint Medicines Corporation’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
